Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical Practice

Sponsor
Bristol-Myers Squibb
Study ID
NCT07663786
Status
Active Not Recruiting

Conditions

  • Esophageal Adenocarcinoma
  • Gastric Adenocarcinoma
  • Gastro-esophageal Junction Adenocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study uses existing cancer registry and health record data to understand how nivolumab is used in routine care in the Netherlands for adults with advanced cancers of the esophagus, gastroesophageal junction, or stomach.

Key Dates

First listed
Jun 23, 2026
Start date
Oct 9, 2025
Status verified
Jun 2026
Primary completion
Oct 1, 2026
Completion
Feb 1, 2027

Study Design

Enrollment
726 participants (estimated)

Arms

  • Arm: Advanced/metastatic EAC/GEJAC/GAC participants
    Participants diagnosed with HER2-negative unresectable advanced (cT4B) or synchronous metastatic (cM1) esophageal adenocarcinoma (EAC), gastro-esophageal junction adenocarcinoma (GEJAC), or gastric adenocarcinoma (GAC)
  • Arm: Cohort 2: Participants eligible for first-line nivolumab
    Subset of Cohort 1 who are eligible for nivolumab treatment according to the European Medicines Association (EMA) approved indication
  • Arm: Cohort 3: Participants treated with first-line nivolumab
    Subset of Cohort 2 who received nivolumab as part of first-line treatment

Primary Outcome Measure

Overall survival (OS) among participants treated with first-line nivolumab [ Time Frame: Up to 24 months ]

Related Studies